ANL

Adlai Nortye Ltd ADR

13.26

Jul 22 • 03:59PM ET +0.26 (2.00%)

13.26

Aftermarket • 04:15PM ET 0.00 (0.00%)

Healthcare Biotechnology China Small NASD

Peers: INCY BMRN VKTX KRYS KYMR NUVL RYTM AXSM MDGL NBIX

| Held by: CANC BBC

Scroll to Statements

Index	-
Market Cap	455.35M
Enterprise Value	457.94M
Income	-35.62M
Sales	5.01M
Book/sh	-0.21
Cash/sh	0.69
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	109
IPO	Sep 29, 2023

P/E	-
Forward P/E	-
PEG	-
P/S	90.89
P/B	-
P/C	19.14
P/FCF	-
EV/EBITDA	-
EV/Sales	91.40
Quick Ratio	0.65
Current Ratio	0.65
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-1.01
EPS next Y	-0.37
EPS next Q	-
EPS this Y	19.82%
EPS next Y	-26.07%
EPS next 5Y	-6.54%
EPS past 3/5Y	14.75% 10.50%
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	Feb 25
EPS/Sales Surpr.	-35.71% -

Insider Own	9.36%
Insider Trans	-0.00%
Inst Own	24.24%
Inst Trans	12.10%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-721.72%
Profit Margin	-710.41%
SMA20	22.35%
SMA50	18.92%
SMA200	86.99%
Trades

Shs Outstand	34.34M
Shs Float	31.12M
Short Float	10.72%
Short Ratio	14.05
Short Interest	3.34M
52W High	17.25 -23.13%
52W Low	0.88 1409.22%
Volatility	15.62% 14.31%
ATR (14)	1.35
RSI (14)	63.86
Beta	1.12
Rel Volume	0.76
Avg Volume	237.32K
Volume	179,988

Perf Week	24.74%
Perf Month	27.50%
Perf Quarter	-16.92%
Perf Half Y	616.76%
Perf YTD	833.80%
Perf Year	755.48%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	28.50
Prev Close	13.00
Price	13.26
Change	2.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-22-26	Initiated	Cantor Fitzgerald	Overweight
May-28-26	Initiated	Oppenheimer	Outperform	$32
Mar-20-26	Initiated	Leerink Partners	Outperform	$23
Feb-13-26	Upgrade	H.C. Wainwright	Neutral → Buy	$16
Jun-02-25	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-04-24	Initiated	H.C. Wainwright	Buy	$9
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$30

Jul-16-26 07:00AM	Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025 (GlobeNewswire) +6.77%
Jul-13-26 07:00AM	Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists (GlobeNewswire) -6.38%
Apr-16-26 07:00AM	Adlai Nortye Announces $150.0 Million Private Placement Equity Financing (GlobeNewswire)
Mar-09-26 09:40AM	Is Adlai Nortye Ltd. Sponsored ADR (ANL) Outperforming Other Medical Stocks This Year? (Zacks)
Feb-19-26 09:40AM	Has Adlai Nortye Ltd. Sponsored ADR (ANL) Outpaced Other Medical Stocks This Year? (Zacks)
04:00AM	Loading…
Feb-12-26 04:00AM	Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations (GlobeNewswire)
Feb-03-26 07:00AM	Adlai Nortye Announces $140.0 Million Private Placement Equity Financing (GlobeNewswire)
Dec-29-25 06:00AM	Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China (GlobeNewswire) +9.76%
Nov-21-25 08:00AM	Adlai Nortye to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.59%
Oct-22-25 12:00AM	Adlai Nortye to Present Short Talk on AN4035 Preclinical Results at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-13-25 11:07PM	Adlai Nortye to Present Short Talk at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire) +5.15%
Apr-10-25 08:00AM	Adlai Nortye to Present Research Findings at AACR Annual Meeting 2025 (GlobeNewswire)
Aug-08-24 08:30AM	Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress (GlobeNewswire)
08:00AM	Adlai Nortye Appoints Roger Sawhney, M.D. to Its Board of Directors (GlobeNewswire)
Jun-04-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
09:03PM	Loading…
May-23-24 09:03PM	Adlai Nortye Ltd. to Present Encouraging Data of the Combination of AN0025 and Definitive Chemoradiotherapy (dCRT) at ASCO 2024 (GlobeNewswire) -5.65% -12.72%
May-22-24 08:00AM	Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0025) for the Treatment of Locally Advanced Rectal Cancer with Radiation Therapy (GlobeNewswire)
May-15-24 09:40AM	Are Medical Stocks Lagging Adlai Nortye Ltd. Sponsored ADR (ANL) This Year? (Zacks) +7.08%
Apr-25-24 09:40AM	Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-29-24 06:00AM	Adlai Nortye Announces Appointment of Dr. Archie Tse as the Head of Research & Development (GlobeNewswire)
Nov-17-23 07:30AM	Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC (GlobeNewswire)
Oct-23-23 08:12AM	Adlai Nortye Ltd. & Nucleai awarded ESMO 2023 BEST Poster Award (GlobeNewswire)
Oct-03-23 12:05PM	Adlai Nortye Ltd. Announces Closing of Initial Public Offering (GlobeNewswire) -6.87%
Sep-29-23 02:46AM	Adlai Nortye Ltd. Announces Pricing of Initial Public Offering (GlobeNewswire)

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.

Co- FounderMr. Yang Lu EMBA

Ph.D.Dr. Ngai Chiu Tse M.D.

Chief Financial OfficerDr. Xiaofeng Ye Ph.D.

Vice President of OperationsDr. Zhiyong Yu Ph.D.

Head of HR & Administration & Government AffairsMr. Chen Yang EMBA

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LU YANG	CEO	May 13 '26	Sale	13.18	10	132	99,990	May 21 12:08 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANL

Adlai Nortye Ltd ADR

Upgrade your Finviz experience